Pigmentary changes in chronic myeloid leukemia patients treated with imatinib mesylate

被引：74
|
作者：
Arora, B [1 ]
Kumar, L [1 ]
Sharma, A [1 ]
Wadhwa, J [1 ]
Kochupillai, V [1 ]
机构：
[1] All India Inst Med Sci, RDHMM, New Delhi 110049, India
来源：
ANNALS OF ONCOLOGY | 2004年 / 15卷 / 02期
关键词：
D O I：
10.1093/annonc/mdh068
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：358 / 359
页数：2
相关论文
共 50 条
  • [21] Predictors of Treatment Non-Adherence in Patients Treated with Imatinib Mesylate for Chronic Myeloid Leukemia
    StCharles, Meaghan
    Bollu, Vamsi K.
    Hornyak, Elizabeth
    Coombs, John
    Blanchette, Christopher M.
    DeAngelo, Daniel J.
    BLOOD, 2009, 114 (22) : 870 - 870
  • [22] HEPATITIS B REACTIVATION IN THE CHRONIC MYELOID LEUKEMIA PATIENT TREATED WITH IMATINIB MESYLATE
    Ozeki, Kazutaka
    Morishita, Yoshihisa
    Suzuki, Tomohiko
    Umemura, Koji
    Yamaguchi, Yohei
    Tatekawa, Shotaro
    Watamoto, Koichi
    Ozeki, Keiji
    Kohno, Akio
    ANNALS OF ONCOLOGY, 2014, 25
  • [23] Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population
    Yanmin Zhao
    Lizhen Liu
    Yingjia Wang
    Gongqiang Wu
    Xiaoyu Lai
    Weijie Cao
    Yi Luo
    Yamin Tan
    Jimin Shi
    Wanzhuo Xie
    Xiujin Ye
    Zhen Cai
    Maofang Lin
    He Huang
    International Journal of Hematology, 2009, 89 : 445 - 451
  • [24] Bilateral Toxoplasma Retinochoroiditis in a Patient with Chronic Myeloid Leukemia Treated with Imatinib Mesylate
    Basu, Soumyava
    Das, Taraprasad
    Biswas, Ghanshyam
    OCULAR IMMUNOLOGY AND INFLAMMATION, 2010, 18 (01) : 64 - 65
  • [25] Efficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese population
    Zhao, Yanmin
    Liu, Lizhen
    Wang, Yingjia
    Wu, Gongqiang
    Lai, Xiaoyu
    Cao, Weijie
    Luo, Yi
    Tan, Yamin
    Shi, Jimin
    Xie, Wanzhuo
    Ye, Xiujin
    Cai, Zhen
    Lin, Maofang
    Huang, He
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2009, 89 (04) : 445 - 451
  • [26] Kaposi's Sarcoma in a Patient Treated With Imatinib Mesylate for Chronic Myeloid Leukemia
    Campione, Elena
    Diluvio, Laura
    Paterno, Evelin J.
    Di Marcantonio, Dely
    Francesconi, Arianna
    Terrinoni, Alessandro
    Orlandi, Augusto
    Chimenti, Sergio
    CLINICAL THERAPEUTICS, 2009, 31 (11) : 2565 - 2569
  • [27] Paradoxical Pandora's box of pigmentary side effects by imatinib mesylate in case of chronic myeloid leukemia
    Pardeshi, Snehal S.
    Havanur, Preeti
    Kharkar, Vidya
    Mahajan, Sunanda
    Khopkar, Uday
    DERMATOLOGIC THERAPY, 2022, 35 (05)
  • [28] Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase
    Kiguchi, Toru
    Tauchi, Tetsuzo
    Ito, Yoshikazu
    Miyazawa, Keisuke
    Kimura, Yukihiko
    Ohyashiki, Kazuma
    LEUKEMIA RESEARCH, 2009, 33 (03) : 506 - 508
  • [29] IMATINIB MESYLATE INDUCED HEPATOTOXICITY IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML)
    Milosevic, V.
    Bogdanovic, A.
    Djordjevic, V.
    Fekete, M. Dencic
    Mihaljevic, B.
    Gotic, M.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 545 - 546
  • [30] Administration of imatinib mesylate in patients with chronic myeloid leukemia with short bowel
    Yamazaki, Rie
    Aisa, Yoshinobu
    Mori, Takehiko
    Iketani, Osamu
    Ikeda, Yasuo
    Okamoto, Shinichiro
    LEUKEMIA & LYMPHOMA, 2009, 50 (04) : 670 - 672
12345